English
Regional settings| Spread | 23.98 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ JP¥5,000 Short position overnight fee ~ JP¥4,000 | -0.011244% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ JP¥5,000 Short position overnight fee ~ JP¥4,000 | -0.010978% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | JPY | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Japan | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4079.75 |
| Open | 4058.6 |
| 1-Year Change | -10.21% |
| Day's Range | 4052.42 - 4077.45 |
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
BRIEF: For the nine months ended 31 December 2021, Takeda Pharmaceutical Co Ltd revenues increased 11% to Y2.696T. Net income applicable to common stockholders increased 35% to Y241.42B. Revenues reflect Intellectual Property And Service Revenue segment increase from Y69.04B to Y210.55B, Pharmaceutical Business segment increase of 5% to Y2.485T, Northern America segment increase of 9% to Y1.297T, Japan segment increase of 22% to Y530.25B.
FY'94-02 WAS were estimated. FY'04 Name changed from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited. All 1&3Q, WAS were estimated and used as O/S. FY'08 Q3 WAS=O/S. FY'11 Q3 DWAS is estimated.
